Such a thoughtful discussion addressing one of the central tensions in modern neurology: how to interpret modest clinical effects in devastating diseases where patients and families are understandably desperate for progress. What I appreciated most is that the article moved beyond simplistic “breakthrough” versus “failure” narratives and instead examined the Alzheimer’s drug landscape with nuance, particularly around endpoints, risk-benefit balance, and mechanistic assumptions. One of the most important points is the distinction between altering a biomarker and meaningfully altering lived cognitive outcomes. The newer anti-amyloid therapies clearly demonstrate that amyloid plaques can be reduced in the human brain, which is scientifically significant. But the larger clinical question is whether plaque reduction translates into substantial preservation of memory, independence, executive function, and quality of life over meaningful time horizons. That gap between biologic effect and functional outcome is where much of the debate appropriately centers. I also appreciated the broader implication that Alzheimer’s disease is probably far more biologically complex than amyloid accumulation alone. Neuroinflammation, vascular dysfunction, insulin resistance, mitochondrial impairment, sleep disruption, immune signaling, synaptic loss, tau pathology, and metabolic aging likely interact over decades before symptoms emerge. The field increasingly feels less like a single-pathway disease model and more like a systems-level neurodegenerative process. At the same time, I think it is important not to dismiss incremental progress simply because it is imperfect. Neurology historically has had relatively few disease-modifying therapies for neurodegeneration, so even modest slowing of decline may matter deeply for patients and families depending on disease stage and risk tolerance. The challenge is communicating those benefits honestly without overstating them, especially given the risks of ARIA (amyloid-related imaging abnormalities), cost considerations, monitoring burden, and unequal access to advanced treatment infrastructure. What I find especially interesting is how these therapies may ultimately reshape the timing of intervention more than late-stage treatment itself. If Alzheimer’s pathology begins decades before cognitive symptoms, the future may depend increasingly on identifying high-risk individuals earlier through genetics, blood biomarkers, retinal imaging, sleep analysis, and longitudinal metabolic profiling rather than waiting for overt impairment. Overall, I believe this piece captured the complexity of the current moment in Alzheimer’s research very well: genuine scientific progress coexisting with important unanswered questions about causality, clinical significance, accessibility, and what successful brain aging prevention will ultimately require. Thanks again for sharing!
The cholinesterase inhibitor comparison reframes the whole discussion in a way that's hard to ignore. The biology clearly differs, but the measurable outcomes don't, at least not yet. Excellent breakdown, Hussein!
Well researched thoughtful post- thank you. I would like to be more optimistic about the anti-amyloid drugs but until real clinical improvement is demonstrated convincingly( especially with the significant risks and cost), I will remain very skeptical. And wouldn’t Pharma just love to move into the primary prevention market here with virtually unlimited customer base?
These are some really interesting insights Dr. Yassine. I wonder where research could go in the future if we don’t see significant positive results from these trials. Do you think that any other particular treatments (perhaps targeting primarily tau) may show any promise?
From other scholarship I read, I saw promise in combination therapy of donepezil and memantine used together, where they appeared to work better when used with each other- I wonder if a similarly multipronged treatment that uses a mix of different monoclonal antibodies could be viable?
I think future research into activating the systems that clear amyloid and tau together with drugs aimed at recalibrating inflammation hold promise. At a fundamental level, we need to better distinguish whether a disease is driven by overproduction of a certain protein or impaired clearance as treatments may differ.
As a health care aide and Homecare worker, I have seen this in use by one of my clients. The improvement was quite good, but the family simply could not afford the treatment. After that the clients decline was rapid. Tragic to see the client return to ‘normal’ and then not. I might advise not bothering at all unless you can afford the long term costs. The heartbreak is not worth it.
Hi Hussein, thank you for this article. I was wondering if you have any similar analysis on obicetrabib based on recently reported biomarker data based on the prespecified part of the Broadway phase 3 trial? I realise there is no readout as yet re clinical changes. Your thoughts would be appreciated. Menarini had made and ema accepted some level of pre marketing application. A near 20% difference between placebo and active drug has been reported in E4/4 group. How exciting or not is this at this stage of information?
Its premature to market indications based on a retrospective analysis of a past trial. These are exciting but yet preliminary and would support a direct trial.
Such a thoughtful discussion addressing one of the central tensions in modern neurology: how to interpret modest clinical effects in devastating diseases where patients and families are understandably desperate for progress. What I appreciated most is that the article moved beyond simplistic “breakthrough” versus “failure” narratives and instead examined the Alzheimer’s drug landscape with nuance, particularly around endpoints, risk-benefit balance, and mechanistic assumptions. One of the most important points is the distinction between altering a biomarker and meaningfully altering lived cognitive outcomes. The newer anti-amyloid therapies clearly demonstrate that amyloid plaques can be reduced in the human brain, which is scientifically significant. But the larger clinical question is whether plaque reduction translates into substantial preservation of memory, independence, executive function, and quality of life over meaningful time horizons. That gap between biologic effect and functional outcome is where much of the debate appropriately centers. I also appreciated the broader implication that Alzheimer’s disease is probably far more biologically complex than amyloid accumulation alone. Neuroinflammation, vascular dysfunction, insulin resistance, mitochondrial impairment, sleep disruption, immune signaling, synaptic loss, tau pathology, and metabolic aging likely interact over decades before symptoms emerge. The field increasingly feels less like a single-pathway disease model and more like a systems-level neurodegenerative process. At the same time, I think it is important not to dismiss incremental progress simply because it is imperfect. Neurology historically has had relatively few disease-modifying therapies for neurodegeneration, so even modest slowing of decline may matter deeply for patients and families depending on disease stage and risk tolerance. The challenge is communicating those benefits honestly without overstating them, especially given the risks of ARIA (amyloid-related imaging abnormalities), cost considerations, monitoring burden, and unequal access to advanced treatment infrastructure. What I find especially interesting is how these therapies may ultimately reshape the timing of intervention more than late-stage treatment itself. If Alzheimer’s pathology begins decades before cognitive symptoms, the future may depend increasingly on identifying high-risk individuals earlier through genetics, blood biomarkers, retinal imaging, sleep analysis, and longitudinal metabolic profiling rather than waiting for overt impairment. Overall, I believe this piece captured the complexity of the current moment in Alzheimer’s research very well: genuine scientific progress coexisting with important unanswered questions about causality, clinical significance, accessibility, and what successful brain aging prevention will ultimately require. Thanks again for sharing!
The cholinesterase inhibitor comparison reframes the whole discussion in a way that's hard to ignore. The biology clearly differs, but the measurable outcomes don't, at least not yet. Excellent breakdown, Hussein!
Well researched thoughtful post- thank you. I would like to be more optimistic about the anti-amyloid drugs but until real clinical improvement is demonstrated convincingly( especially with the significant risks and cost), I will remain very skeptical. And wouldn’t Pharma just love to move into the primary prevention market here with virtually unlimited customer base?
These are some really interesting insights Dr. Yassine. I wonder where research could go in the future if we don’t see significant positive results from these trials. Do you think that any other particular treatments (perhaps targeting primarily tau) may show any promise?
From other scholarship I read, I saw promise in combination therapy of donepezil and memantine used together, where they appeared to work better when used with each other- I wonder if a similarly multipronged treatment that uses a mix of different monoclonal antibodies could be viable?
Dear Lucas
I think future research into activating the systems that clear amyloid and tau together with drugs aimed at recalibrating inflammation hold promise. At a fundamental level, we need to better distinguish whether a disease is driven by overproduction of a certain protein or impaired clearance as treatments may differ.
As a health care aide and Homecare worker, I have seen this in use by one of my clients. The improvement was quite good, but the family simply could not afford the treatment. After that the clients decline was rapid. Tragic to see the client return to ‘normal’ and then not. I might advise not bothering at all unless you can afford the long term costs. The heartbreak is not worth it.
The ability of these drugs to penetrate the blood / brain barrier is in itself a big plus, no? Am I correct that hadnt been possible before?
These drugs penetrate the BBB
It is a plus
They prime the microglia inside the brain to clear amyloid plaques
The problem is when they stick to brain blood vessels and trigger an immune response
Newer generation drugs are designed to shuttle from vessels into the brain, limiting vascular complications such as ARIA
Hi Hussein, thank you for this article. I was wondering if you have any similar analysis on obicetrabib based on recently reported biomarker data based on the prespecified part of the Broadway phase 3 trial? I realise there is no readout as yet re clinical changes. Your thoughts would be appreciated. Menarini had made and ema accepted some level of pre marketing application. A near 20% difference between placebo and active drug has been reported in E4/4 group. How exciting or not is this at this stage of information?
Its premature to market indications based on a retrospective analysis of a past trial. These are exciting but yet preliminary and would support a direct trial.
Thanks, we will see how it plays out. I believe a specific , rather than prespecified sub group trial is planned for q3 this year.